Document is current

Any future updates will be listed below

Letter to the Editor Regarding “Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States”

Crossref DOI link: https://doi.org/10.1007/s12325-023-02596-w

Published Online: 2023-07-11

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark